Christine Lu | Co-Director of the PRecisiOn Medicine Translational Research (PROMoTeR) Center
Harvard Pilgrim Health Care

Christine Lu, Co-Director of the PRecisiOn Medicine Translational Research (PROMoTeR) Center, Harvard Pilgrim Health Care

Christine Lu MSc, PhD is an Associate Professor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute and she co-directs the PRecisiOn Medicine Translational Research (PROMoTeR) Center. She is a pharmacist, health policy scientist and pharmacoepidemiologist. After receiving an MSc (Biopharmaceuticals) and a PhD in Clinical Pharmacology from the University of New South Wales, Australia, Dr. Lu completed her post-doctoral training at Harvard Medical School.
Dr. Lu leads the precision medicine & policy, and precision medicine oncology portfolios for the DPM. Her research focuses on the policy, legal, ethical, economic and societal issues of precision medicine, which have substantial impacts on the coverage and reimbursement and clinical integration of genomic testing and sequencing. She is Co-Principal Investigator of Genomics-based Technologies: Access and Reimbursement Issues. Dr. Lu co-leads the Genetic and Molecular Tests Data Workgroup for the Cancer Research Network.  She also conducts research to assess real-world utility of genomic testing and sequencing, including the impact of value-based contracts. 

Appearances:



Pharma Pricing & Market Access USA Day 2 @ 11:00

PANEL: Value based frameworks for precision medicine

  • Are current value frameworks suited to precision medicine?
  • What factors should be considered?
  • What are the ethical perspectives? 
Moderator: Christine Lu, Co-Director of the PRecisiOn Medicine Translational Research (PROMoTeR) Center, Harvard Pilgrim Health Care
john mattison, CHIO, Asst Med Dir, Kaiser Permanente
Selin Kurnaz, Co-founder and CEO, Massive Bio
Nneka Onwudiwe PharmD PhD MBA, PRO/PE Regulatory Reviewer, US Government
Catherine Brownstein, Scientific Director, Manton Center for Orphan Disease Research
James Barbeau, Director of Clinical Pathology, Lifespan/Brown University
Surrey Walton, Associate Professor of Pharmacy Administration, U.I.C.

Pharma Pricing & Market Access USA Day 2 @ 12:20

ROUND TABLES

1) Global Market Access For Orphan Drugs - How to include developing countries

  • Durhane Wong-Rieger, President, Canadian Organization for Rare Disorders
  • Ron Marchessault, Vice President, Value and Access, Specialty Care Sanofi Genzyme
  • Ramaiah Muthyala, President, Indian Organization for Rare Diseases
  • George Wyatt, Executive Senior Consultant, Innomar Strategies, Amerisource Bergen
  • Lisa Phelps, VP Policy, NORD National Organization for Rare Diseases
  • Meryem Nimour, VP- Medical Affairs Lead – Rare Disease- Emerging Markets, Pfizer
  • Pam Gavin, Chief Operating Officer, National Organization for Rare Diseases
2) Patient led Evidence - Discussing new levels of patient centricity in pricing models
  • Bert Vrijhoef, CIO & Senior Principal, Investigator, Panaxea & Maastricht University Medical Center
  • Lauren Bartolome, HEOR fellow, Novartis
  • Nneka Onwudiwe, PRO/PE Regulatory Review Officer, US Government​
3) I/O Pricing Models- New models to stumulate a fluctuating market
  • Bhakti Arondekar, Sr Director, Outcomes & Evidence, Oncology, Pfizer
  • Alberto Batista, HEOR fellow, Jefferson College of Population Health
  • Francisco Burgin, PGY-1 Managed Care Pharmacy Resident, Humana
4) Asian Access and Reimbursement- Discussing new developments in HTA in Asia
  • Jack Shea, Director Corporate Development, Merck
  • Sean McElligott, Director, Market Access, Janssen
  • Elizabeth Richardson, Managing Associate, Duke Margolis Center for Health Policy
5) Paying for gene therapy- Single fix medication and pricing models
  • John Maslowski, President and CEO, Fibrocell
  • Timothy Miller, President, CEO and Director, Abeona Therapeutics Inc
  • Christine Lu, Associate Professor, Harvard Medical School & Harvard Pilgrim Health Care Institute
  • Marianne Hamilton Lopez, Research Director, Duke-Robert J. Margoli Centre for Health Policy
6) Brazil Focus: Market Acess and Value Generation
  • Christina Matteucci, Market Access Head, Brazil, Bristol Myers Squibb
  • Roberta Monteiro, Market Access and Commercial Director, Eisai Brasil
7) Pluralistic approaches to value - Does the one size fits all approach still work?
  • Shanthy Krishnaraja, Global Head of Health Economics and Reimbursement Strategy, CSL Behring
  • Ashley John, Senior Specialist, Advocacy and Policy, American Academy of Dermatology

8) One payer systems - Consequences of implementation

  • Stephen Smith, Reimbursement Associate, Merck

Paying for gene therapy- Single fix medication and pricing models

back to speakers